Plain-English translation of NCT07064707 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ulcerative Colitis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called can help people with ulcerative colitis feel better when combined with standard treatment. Half of the participants will take the standard medication alone, while the other half will take the standard medication plus . The study will run for 3 months to see if this treatment is safe and works better than the standard approach.
Ulcerative colitis is a chronic condition that causes lasting inflammation in the colon and rectum, and current treatments don't work well enough for everyone. Researchers want to see if adding this medication to standard care can help control inflammation and improve symptoms more effectively.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups for 3 months. One group will take (the standard treatment) three times daily, while the other will take the same plus the new medication once daily. You'll likely have clinic visits to check on your symptoms, side effects, and how well the treatment is working.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Egypt
Phase
Testing effectiveness
Sponsor
Alexandria University
Collaborators
Prof. Dr. Ahmed Ibrahim Mohammed El Mallah, faculty of pharmacy, Alexandria University., Assoc. Prof. Dr. Noha Alaa Eldin Hassan Hamdy, Faculty of pharmacy, Alexandria University.
Enrollment target
~60 participants
Started
July 2025
Primary completion
July 2026
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Reham Elshafiey, PhD
Alexandria University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.